Furthermore, the correlation described between RAC1 overactivation and PD-L1 expression56,57 suggests that RAC1 inhibition in combination with anti-PD/PD-L1 (PD-L1, programmed death-ligand 1) immunotherapy or other agents that potentiate anti-tumor immune responses could represent a promising therapeutic strategy. This evidence concerns the gene CD274 and neoplasm.